{
"id":"mk19_b_pm_t12",
"number":12,
"bookId":"pm",
"title":{
"__html":"Recommended Pharmacologic Management of COPD by GOLD Classification"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"f66a96",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 12. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_pm_t12"
}
]
},
"Recommended Pharmacologic Management of COPD by GOLD Classification"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a59220",
"class":"col hd l",
"children":[
"Patient Group"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f05b9",
"class":"col hd l",
"children":[
"Recommended Therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"034a47",
"class":"col hd l",
"children":[
"Alternative Therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f7db1b",
"class":"col hd l",
"children":[
"Other Considerations"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7fc562",
"class":"cell txt l",
"children":[
"A"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"848c74",
"class":"cell txt l",
"children":[
"Short-acting bronchodilator ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
}
]
},
" ",
{
"type":"p",
"hlId":"c036fb",
"class":"cell txt l",
"children":[
"Long-acting bronchodilator"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9f43c",
"class":"cell txt l",
"children":[
"Evaluate effect of therapy and continue, stop, or try alternative bronchodilator as appropriate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2abf01",
"class":"cell txt l",
"children":[
"All patients in group A should receive bronchodilator therapy based on its effect on dyspnea; therapy should be continued if symptomatic benefit is documented."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d5ed6",
"class":"cell txt l",
"children":[
"B"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"73c36c",
"class":"cell txt l",
"children":[
"Long-acting bronchodilator (LABA or LAMA) ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
}
]
},
" ",
{
"type":"p",
"hlId":"a022df",
"class":"cell txt l",
"children":[
"Combination therapy with two bronchodilators may be considered for patients with severe dyspnea"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"351804",
"class":"cell txt l",
"children":[
"If symptoms persist after one long-acting bronchodilator, try combined therapy with LABA and LAMA"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e3b14d",
"class":"cell txt l",
"children":[
"Long-acting inhaled bronchodilators are superior to short-acting bronchodilators received as needed."
]
},
" ",
{
"type":"p",
"hlId":"5bec70",
"class":"cell txt l",
"children":[
"There is no evidence to support use of one class of long-acting bronchodilators over another for initial relief of symptoms for patients in group B. In the individual patient, the choice should depend on the patient's perception of symptom relief."
]
},
" ",
{
"type":"p",
"hlId":"d1f832",
"class":"cell txt l",
"children":[
"Patients in group B are likely to have comorbidities that affect symptoms and prognosis, and these should be investigated."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0d61f8",
"class":"cell txt l",
"children":[
"C"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"56b35f",
"class":"cell txt l",
"children":[
"LAMA; if further exacerbations, LAMA and LABA"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b03ff7",
"class":"cell txt l",
"children":[
"LABA and inhaled glucocorticoids"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"94a9f5",
"class":"cell txt l",
"children":[
"LABA and LAMA is preferred to LABA and inhaled glucocorticoids because inhaled glucocorticoids increase the risk of developing pneumonia in some patients."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f623e7",
"class":"cell txt l",
"children":[
"D"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6ffd45",
"class":"cell txt l",
"children":[
"LAMA or"
]
},
" ",
{
"type":"p",
"hlId":"fa7d0a",
"class":"cell txt l",
"children":[
"LAMA and LABA",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
}
]
},
" ",
{
"type":"p",
"hlId":"334474",
"class":"cell txt l",
"children":[
"Inhaled glucocorticoids and LABA",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e408fd",
"class":"cell txt l",
"children":[
"If exacerbations continue, consider:"
]
},
" ",
{
"type":"p",
"hlId":"8c310e",
"class":"cell txt l",
"children":[
"Roflumilast (patients with an FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
" <50% of predicted and chronic bronchitis, particularly if they have experienced at least one hospitalization for an exacerbation in the previous year) ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
}
]
},
" ",
{
"type":"p",
"hlId":"6b7e6b",
"class":"cell txt l",
"children":[
"Macrolide therapy (the best available evidence exists for the use of azithromycin)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"729b7f",
"class":"cell txt l",
"children":[
"Initial therapy with LABA and inhaled glucocorticoids may be appropriate in some patients, including those with a history or findings suggestive of asthma."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"GOLD = Global Initiative for Chronic Obstructive Lung Disease; LABA = long-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist; LAMA = long-acting muscarinic agent."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Consider if highly symptomatic."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Consider if eosinophils >300/μL (0.30 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)."
],
[
"Information from Global Initiative for Chronic Obstructive Lung Disease, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2020 report. Accessed September 27, 2020. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://goldcopd.org/gold-reports/",
"target":"_blank"
},
"children":[
"https://goldcopd.org/gold-reports/"
]
}
]
]
}